Emerging biopharmaceutical companies constitute one of the true hubs of innovation in today’s drug development ecosystem. However, most operate under constrained resources in terms of management bandwidth and available capital. In addition, many companies may have only one asset in clinical development. Therefore, maximizing results in development is essential to continued success.
While emerging biopharmas have deep scientific expertise around a specific therapeutic area or indication, in-house clinical trial experience can be limited. This webinar is intended to help emerging biopharma companies explore some of the key steps they can take to accelerate timelines and improve their probability of successfully demonstrating value. Our experienced panelists will address how to:
- Design your trials, from the very start, with the end in mind to gather the necessary evidence
- Understand your product’s realistic target profile and patient populations earlier in the development process
- Leverage genetic profiling to better identify and access the right patients · accelerate critical study start-up activities to improve overall timelines
- Utilize tailored risk-based monitoring approaches to maximize efficiency
- Explore the advantages of using adaptive trial design
- Partner with experts more effectively to take greater advantage of multiple data sources, analytics and global relationships
Josh Rose, Vice President, Enterprise Offering Development, Quintiles
As head of New Offerings Development for Quintiles, Josh Rose is responsible for bringing to market new services to better meet our customers’ needs and drive continued growth. He oversees the innovation process, development and market launch of new clinical services and solutions. Previously, Josh served as head of strategy for Quintiles’ Clinical Development which included setting the overall clinical business strategy and identifying acquisition candidates.
Before joining Quintiles Josh held various product strategy and marketing strategy leadership positions across a range of company sizes, all largely focused on healthcare technology. He developed his strategic skills working for Diamond Management, a technology focused management consulting firm which was acquired by PWC.
Josh has an MBA from Duke University and a BsC in Chemical Engineering from the University of Illinois in Campaign-Urbana.
Brad Smith, Ph.D., Vice President, Translational Medicine, Center for Integrated Drug Development, Quintiles
As the VP of Translational Medicine in the Center for Integrated Drug Development within Quintiles, Brad Smith leads biomarker and companion diagnostic strategy and planning interactions throughout the organization including clinical, laboratory, consulting and commercial projects. He brings more than 20 years of experience in biological research in academia, biotechnology and clinical services including 5 years of experience in planning and design of clinical development plans and protocols.
Prior to Quintiles, Brad spent 10 years at Cell Signaling Technology responsible for technical and corporate development of biomarker and diagnostic businesses.
Brad is the author of multiple basic research, translational medicine and clinical publications and patents and has held Ph.D. and post-doctoral positions at Stanford University and University of California, San Francisco.
Dr. Christoph Schnorr, Vice President, Drug Development Consulting Europe, Quintiles
Based in Frankfurt, Germany, Dr. Schnorr has 30 years of technical knowledge and operational expertise related to all facets of healthcare, specializing in research & development in the bioPharmaceutical industry. He is a strategic and growth-oriented business executive with a solid foundation in general management principles, healthcare and financial acumen. He also has extensive cross-functional leadership experience with a particular focus on Clinical Development.
Most recently, Christoph was Head of Global Clinical Operations, Head of Development Operations (Managing Director) and Chief Medical Officer for a global Pharmaceutical company. In a previous role, he served as R&D Service Line Lead Partner for Europe, Latin America and Africa (EALA) at Accenture. Dr. Schnorr holds a medical degree and is trained as an Anesthesiologist and Clinical Pharmacologist.
Who Should Attend?
- Senior level executives from emerging biopharmaceutical companies
- Chief medical and scientific officers from emerging biopharmaceutical companies
- Biopharmaceutical investors, including venture capital and private equity
- Therapeutic area clinical development heads
- Clinical development program leaders or managers
- Procurement/outsourcing managers
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of bioPharmaceutical development and commercial outsourcing services. With a network of more than 29,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.